DIA
SUPN icon

Dean Investment Associates’s Supernus Pharmaceuticals SUPN Stock Holding History

Dean Investment Associates’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-137,875
Closed -$3.27M – 262
2019
Q4 		$3.27M Buy
137,875
+85,460
+163% +$2.08M 0.51% 83
2019
Q3 		$1.44M Buy
+52,415
New +$1.55M 0.21% 148

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dean Investment Associates's SUPN Position: Q1 2020 in Review

Dean Investment Associates sold out of Supernus Pharmaceuticals (SUPN) in Q1 2020, closing a stake of 137,875 shares — an estimated $3.27M sold.

Dean Investment Associates first reported a position in SUPN in Q3 2019 and held it in 2 quarters. The position peaked at $3.27M in Q4 2019. 208 funds tracked by Wall St. Rank hold SUPN as of Q1 2020.

  • Dean Investment Associates reported no remaining Supernus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Dean Investment Associates sold 137,875 Supernus Pharmaceuticals shares in Q1 2020, an estimated $3.27M.
  • Dean Investment Associates first reported a position in Supernus Pharmaceuticals in Q3 2019 and held it in 2 quarters.
  • Dean Investment Associates's Supernus Pharmaceuticals position peaked at $3.27M in Q4 2019.
  • 208 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2020.

Based on Dean Investment Associates's 13F filing for Q1 2020, filed 14 May 2020.